Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study-Reference-Cited by-同舟云学术

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Published:2018-10-22 Issue:2 Volume:25 Page:515-523
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Xu Jianming,Zhang Yun,Jia Ru,Yue Chunyan,Chang Lianpeng,Liu Rongrui,Zhang Gairong,Zhao Chuanhua,Zhang Yaoyue,Chen Chunxia,Wang Yan,Yi Xin,Hu Zhiyuan^ORCID,Zou Jianjun,Wang Quanren

Funder

Jiangsu Hengrui Medicine Co. Ltd.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 390 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics;Molecular Cancer;2024-09-13

2. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

3. Camrelizumab Combined with Transcatheter Arterial Chemoembolization for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis;Clinics and Research in Hepatology and Gastroenterology;2024-09

4. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study;European Journal of Cancer;2024-09

5. Camrelizumab Combined with Apatinib for Portal Vein Tumor Thrombus in Advanced Hepatocellular Carcinoma: Two Case Reports;British Journal of Hospital Medicine;2024-08-30